孟鲁司特纳治疗小儿咳嗽变异性哮喘的临床探讨

Clinical Observation on Treating Children Cough Variant Asthma with Montelukast

目的探讨孟鲁司特纳治疗小儿咳嗽变异性哮喘的临床效果。方法将就诊于该院的75例咳嗽变异性哮喘患儿按照随机数字表法分为对照组37例和观察组38例。对照组患儿单纯给予沙丁胺醇0.25 mL雾化吸入;观察组患者则联合给予孟鲁司特钠咀嚼片口服,连续治疗2个月。观察患儿咳嗽的缓解情况,计算临床治疗的有效率;记录两组患儿咳嗽的消失时间;检测患儿血清炎性细胞因子水平的变化情况,随访3个月观察复发率。结果观察组患儿的有效率92.1%明显高于对照组的有效率73%(P<0.05);观察组患儿的咳嗽消失时间较对照组患儿更快(P<0.05);两组患儿炎性细胞因子白细胞介素-6(IL-6)、肿瘤坏死因子(TNF-α)较治疗前降低明显,观察组患儿的降低程度较对照组更突出(P<0.05);观察组患儿的复发率5.3%明显低于对照组的复发率8.1%(P>0.05)。结论孟鲁司特纳治疗CVA疗效确切,能有效缩短病程,抗炎作用明显,值得临床推广。

Objective To investigate the clinical efficacy of treating Children cough variant asthma with montelukast. Methods 75 Cough Variant Asthma with Montelukast Children were randomly divided into a control group of 37cases and an observation group of 38cases. Patients in the control group were treated with 0.25 mL salbutamol for aerosol inhalation,2times/day,7-10 days for a course; while patients in the observation group were treated with montelukast sodium chewable tablets, 1time/day,2 months for treatment. We observed the improvement of cough symptom and calculated the effective clinical treatment; We recorded the disap-pearance time of cough and tested the level change of serum inflammatory cytokines. We observed the recurrence rate follow-up of 3 months. Results The efficiency for patients in the observation group is92.1%, which was higher than that in the control group 73%（P〈0.05）;The patients＆#39; disappearance time of cough in the observation group was quicker than that in the control group （P〈0.05）;The level of IL-6、TNF-αin the two groups was lower than before treatment, the degree of change in the observation group was more pronounced （P〈0.05）;The recurrence rate for patients in the observation group is5.3%, which was lower than that in the control group 8.1% （P〉0.05）. Conclusion Treating Children cough variant asthma with montelukast has definite curative effect. The therapy can effectively shorten the duration of symptoms, which has a significant anti-inflammatory effect, is worthy of further research and development.